Moomoo AIのまとめ
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a recent Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated June 28, 2024, is an amendment (Amendment No. 12) to a series of previous amendments and the initial Schedule 13D filed on June 1, 2022. This latest amendment involves two reporting persons, CBI USA, Inc., and DGP Co., Ltd., both of which have disclosed significant ownership stakes in Exicure. CBI USA, Inc., a Delaware-based entity, reported owning 818,299 shares, representing 9.5% of the company, while DGP Co., Ltd., based in the Republic of Korea, reported a substantial holding of 3,060,000 shares, amounting to 35.4% of Exicure. The amendment also details contractual arrangements, including an extension of the closing date for the balance of the DGP Sale to July 31, 2024, and an extension of the settlement date for a Stock Loan to December 31, 2024. The filing was certified by Kyungwon Oh, the Chief Executive Officer of both CBI USA, Inc. and DGP Co., Ltd.
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a recent Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated June 28, 2024, is an amendment (Amendment No. 12) to a series of previous amendments and the initial Schedule 13D filed on June 1, 2022. This latest amendment involves two reporting persons, CBI USA, Inc., and DGP Co., Ltd., both of which have disclosed significant ownership stakes in Exicure. CBI USA, Inc., a Delaware-based entity, reported owning 818,299 shares, representing 9.5% of the company, while DGP Co., Ltd., based in the Republic of Korea, reported a substantial holding of 3,060,000 shares, amounting to 35.4% of Exicure. The amendment also details contractual arrangements, including an extension of the closing date for the balance of the DGP Sale to July 31, 2024, and an extension of the settlement date for a Stock Loan to December 31, 2024. The filing was certified by Kyungwon Oh, the Chief Executive Officer of both CBI USA, Inc. and DGP Co., Ltd.
バイオテクノロジー企業であるExicure, Inc.は、NASDAQの歩み値XCURで取引されており、最近、米国証券取引委員会（SEC）に対してスケジュール13D/Aの提出対象となっています。この提出は、2022年6月1日に初めて提出された一連の以前の修正と初期のスケジュール13Dの修正（Amendment No. 12）です。この最新の修正には、CBI USA,Inc.とDGP Co., Ltd.の2つの報告者が関与し、両社ともExicureの重要な所有権を開示しています。デラウェア州に拠点を置くCBI USA, Inc.は、818,299株を保有し、同社の株式の9.5％を占め、韓国に拠点...すべて展開
バイオテクノロジー企業であるExicure, Inc.は、NASDAQの歩み値XCURで取引されており、最近、米国証券取引委員会（SEC）に対してスケジュール13D/Aの提出対象となっています。この提出は、2022年6月1日に初めて提出された一連の以前の修正と初期のスケジュール13Dの修正（Amendment No. 12）です。この最新の修正には、CBI USA,Inc.とDGP Co., Ltd.の2つの報告者が関与し、両社ともExicureの重要な所有権を開示しています。デラウェア州に拠点を置くCBI USA, Inc.は、818,299株を保有し、同社の株式の9.5％を占め、韓国に拠点を置くDGP Co., Ltd.は、3,060,000株を保有し、Exicureの35.4%に相当します。修正では、DGP Saleの残高の締め切り日を2024年7月31日まで延長する契約上の取り決め、およびストックローンの決済日を2024年12月31日まで延長する契約上の取り決めも詳述されています。なお、この提出書は、CBI USA, Inc.とDGP Co., Ltd.の最高経営責任者であるKyungwon Oh氏の認証を得ています。
役に立った
役に立たない